Treatment-resistant depression: Managed care considerations

Journal of Managed Care Pharmacy

Volumn 13, Issue 6 SUPPL. A, 2007, Pages

  Tierney II, John G ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cost effectiveness; Depression; Economic model; Managed care; SNRI; SSRI; Switch; Treatment resistant; Venlafaxine extended release (XR)

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOPAMINE UPTAKE INHIBITOR; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SELEGILINE; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ANTICHOLINERGIC SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG DOSE TITRATION; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECONOMIC EVALUATION; ENZYME INHIBITION; HAMILTON SCALE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEART DISEASE; HUMAN; HYPOTENSION; MAJOR DEPRESSION; MANAGED CARE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROTEIN SYNTHESIS INHIBITION; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; HUMANS; MANAGED CARE PROGRAMS; MODELS, ECONOMIC; PRACTICE GUIDELINES; TERMINOLOGY; TREATMENT FAILURE;

EID: 34548201149     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Kessler RC, Berflund P, Demler O, et al. The epidemiology of major depressive disorder. Results from the national comorbidity replication (NCS-R). JAMA. 2003;289:3095-3105.
3. Murphy JM, Laird NM, Monson RR, et al. A 40-year perspective on the prevalence of depression: the Stirling County Study. Arch Gen Psychiatry. 2000;57:209-15.
4. U.S. Dept. of Health and Human Services. Mental health: a report of the surgeon general. Rockville, MD: U.S. Dept. of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health; 1999. Available at: http://www.surgeongeneral.gov/library/mentalhealth/chapter4/Sec3_1.html. Accessed February 27, 2007.
5. National Institute of Mental Health. Depression. Available at: http://www.nimh.nih.gov/publicat/depression.cfm#ptdep1. Accessed June 16, 2006.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000:356-57.
7. Bland RC. Epidemiology of affective disorders: a review. Can J Psychiatry. 1997;142:367-77.
8. Bruce SE, Weisberg RB, Dolan RT, et al. Trauma and posttraumatic stress disorder in pnmary care patients. Primary Care Companion. J Clin Psychiatry. 2001;3(5):211-17.
9. Molnar BE, Buka SL, Kessler RC. Child sexual abuse and subsequent psychopathology: results from the National Comorbidity Survey. Am J Public Health. 2001;91:753-60.
10. Cheong J, Herkov M, Goodman W. Risk factors associated with depression. Available at: http://psychcentral.com/library/depression_risk.htm. Accessed June 12, 2006.
11. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465-75.
12. Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA. 2003;289:3135-44.
13. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-18.
14. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction. Circulation. 1996;94:3123-29.
15. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease. Arch Gen Psychiatry. 1998;55:580-92.
16. Bostwick JM, Pankratz VS. Affective disorder and suicide risk: a reexamination. Am J Psychiatry. 2000;157:1925-32.
17. Pies R. Handbook of Essential Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press Institute; 2005:19-138.
18. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653-61.
19. Claxton AJ, Li Z, McKendrick J. Selective serotonin reuptake inhibitor treatment in the UK: risk of relapse or recurrence of depression. Br J Psychiatry. 2000;177:163-68.
20. Eaddy MT, Druss BG, Sarnes MW, et al. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy - results from a managed care administrative claims database. J Manag Care Pharm. 2005;11(2):145-50. Available at: http://www.amcp.org/data/jmcp/ Original%20Research-145-150.pdf. Accessed February 27, 2007.
21. Baldomero EB, Ubago JG, Cercós CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS Study. Depress Anxiety. 2005; 22:68-76.
22. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry. 1991;52 (suppl 5):28-34.
23. Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry. 2000;22:153-62.
24. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of the illness? Am J Psychiatry. 2000;157:1501-04.
25. Nierenberg AA, Wright EC. Evolution of remission as a new standard in the treatment of depression. J Clin Psychiatry. 1999;60:7-11.
26. Nierenberg AA, DeCecco L. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16):5-9.
27. Greenberg P, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22(6):363-73.
28. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1-2):83-91.
29. Thase ME, Rush AJ. Treatment resistant depression. In: Bloom PE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press, Ltd.; 1995:1081-97.
30. O'Reardon AA, Amsterdam JD. Treatment-resistant depression: progress and limitations. Psychiatr Ann. 1998;28(11):633-40.
31. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Major Depressive Disorder. 2nd ed. Arlington, VA: American Psychiatric Association; 2000.
32. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venIafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354(12):1231-42.
33. American Psychiatric Association. Treatment recommendations for patients with major depressive disorder. Available at: http://www.psych.org/ psycti_pract/treatg/pg(Depression2e.book-7.cfm. Accessed June 16, 2006.
34. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to cost of care. Am J Manag Care. 1996;2:1239-46.
35. Sheehan DV, Eaddy MT, Shah MB, Mauch RP. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. Am J Manag Care. 2005;11:S354-61.
36. Hoffman L, Enders J, Luo J, et al. Impact of an antidepressant management program on medication adherence. Am J Manag Care. 2002;9:70-80.
37. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA. 1995;273(13):1026-31.
38. Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med. 2000;9(8):700-08.
39. Simon GE, Ludman EJ, Tutty S, et al. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. JAMA. 2004;292(8):935-42.
40. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
41. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161-72.
42. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006:354(12):1243-52.
43. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry. 1997;58:16-21.
44. Kruzikas D, Khandher RK, McLaughlin T, Tedesch M. Patterns of antidepressant use and cost implications of product switching. Poster presented at: Academy of Managed Care Pharmacy Educational Conference; October 5-8, 2006; Nashville, TN.
45. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
46. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-89.
47. Kroenke K, Spitzer RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatric Ann. 2002;32:509-21.
48. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depression Symptomatology (QIDS), Clinician Rating (QU+IDS-C), and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573-83.